Cite
Tucker MD, Brown LC, Chen YW, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9(1):80doi: 10.1186/s40364-021-00334-4.
Tucker, M. D., Brown, L. C., Chen, Y. W., Kao, C., Hirshman, N., Kinsey, E. N., Ancell, K. K., Beckermann, K. E., Davis, N. B., McAlister, R., Schaffer, K., Armstrong, A. J., Harrison, M. R., George, D. J., Rathmell, W. K., Rini, B. I., & Zhang, T. (2021). Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker research, 9(1), 80. https://doi.org/10.1186/s40364-021-00334-4
Tucker, Matthew D, et al. "Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma." Biomarker research vol. 9,1 (2021): 80. doi: https://doi.org/10.1186/s40364-021-00334-4
Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, Rathmell WK, Rini BI, Zhang T. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021 Nov 03;9(1):80. doi: 10.1186/s40364-021-00334-4. PMID: 34732251; PMCID: PMC8564988.
Copy
Download .nbib